$3.12
Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM
Sana (SANA) Upgraded to Buy: Here's What You Should Know
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Overview
52-week range
$2.26
$6.55
20% of range
Avg surprise (last 3)
+11.9%
Avg reaction (last 2)
+3.9%
100% positive
Latest IV / EM
135%
EM ±31.0% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.14 | $-0.15 | +6.7% | +30.0% | +1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.16 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.16 | $-0.20 | +20.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.20 | $-0.22 | +9.1% | — | +6.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.25 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.21 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.49 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | — | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.59 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.15 | -$0.16 | +6.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-49M | — | $-44M | $-95M | $-51M | — | $-62M | $-49M |
| Net income | $-47M | — | $-42M | $-94M | $-49M | — | $-60M | $-50M |
| EPS (diluted) | $-0.17 | — | $-0.16 | $-0.39 | $-0.21 | — | $-0.25 | $-0.21 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $84M | $72M | $103M | $71M | $96M | $128M | $127M | $135M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $112M | $149M | $162M | $83M | $113M | $161M | $210M | $263M |
| Total assets | $374M | $417M | $435M | $362M | $445M | $501M | $559M | $619M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $254M | $256M | $240M | $239M | $236M | $251M | $267M | $279M |
| Total equity | $119M | $161M | $195M | $123M | $209M | $251M | $292M | $340M |